A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
Conditions
Brain Cancer - Cancer - Solid Tumor - Lymphoma
Conditions: official terms
Lymphoma
Conditions: Keywords
18F-FLT, Positive Emission Tomography, Cancer
Study Type
Interventional
Study Phase
Phase 1/Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Intervention
Name: 18F-FLT
Type: Biological
Overall Status
Recruiting
Summary
The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images. Tumour growth rate is a useful indicator of tumour aggression and response to treatment. Imaging and measuring the cell growth with 18F-FLT may be useful in monitoring response to anticancer treatment.
Detailed Description
Clinical trial is a combined Phase I/II imaging, open label, single site study in patients with known or suspected carcinoma of the lung, breast, renal cell, pancreas or brain, and with gastrointestinal malignancies, neuroendocrine tumours, or lymphoma. One 18F-FLT PET scan will be performed in 10 Phase I patients, and pre-injection and post-imaging blood work and vital signs will be collected. Up to 5 18F-FLT PET scans will be performed in 170 Phase II patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 16 Years
Gender: Both
Criteria: Inclusion Criteria:

- Male or female greater than or equal to 16 years of age. If female of child-bearing potential and outside of the window of 10 days since the first day of last menstrual period, a negative pregnancy test is required.

- Patients with known primary or suspected primary, recurrent or metastatic carcinoma of the lung, breast, renal cell, pancreas or brain (including GGM, oligodendrogliomas, and brain metastases from any primary tumour) and with gastrointestinal malignancies, neuroendocrine tumours (including carcinoid and islet cell malignancies, or lymphoma, with at least one lesion >1 cm in diameter.

- Biochemical parameters as measured are required to be within 5 times the normal limits for age.

- Able and willing to follow instruction and comply with the protocol

- Provide written informed consent prior to participation in the study

- Karnofsky Performance Scale Score 50-100

Exclusion Criteria:

- Previous removal of entire tumour

- Biochemical parameters as measured outside 5 times the normal limits for age

- Unable or unwilling to follow instructions and comply with the protocol

- Unable or unwilling to provide written informed consent prior to participation in the study

- Karnofsky Performance Scale Score < 50

- Nursing or pregnant females

- Age less than 16 years
Location
Cross Cancer Institute
Edmonton, Alberta, Canada
Status: Recruiting
Start Date
February 2009
Completion Date
December 2015
Sponsors
AHS Cancer Control Alberta
Source
AHS Cancer Control Alberta
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page